- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05478785
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Xianying Piao, doctor
- Phone Number: +86-17813168890
- Email: piaoxianying@mail.ecspc.com
Study Locations
-
-
Jilin
-
Changchun, Jilin, China, 130000
- Jilin Cancer Hospital
-
Contact:
- Ying Cheng, chief physician
- Phone Number: 15044044052
- Email: 1165095416@qq.com
-
Principal Investigator:
- Ying Cheng, Doctor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 to 70 years (inclusive), no gender limitation;
- Stage I: patients with advanced, recurrent or metastatic solid tumors confirmed by histology or cytology, and no standard treatment, or ineffective or intolerable to standard treatment, or those who are not eligible to receive standard treatment; Stage II: Pending;
- Have at least one measurable lesion according to RECIST v1.1;
- Eastern Cooperative Oncology Group (ECOG) physical performance status score of 0-1;
- Life expectancy of at least 3 months;
Major organ function within 7 days prior to treatment, meeting the following criteria (have not received blood transfusion, EPO, G-CSF or other medical supportive treatment within 14 days before study drug administration):
Blood routine:
- Neutrophil absolute value (ANC) ≥ 1.5 × 10^9/L;
- Platelet (PLT) ≥ 90× 10^9/L;
- Hemoglobin (HB) ≥ 90 g/L;
Renal function:
- Creatinine (Cr) ≤ 1.5 × ULN;
- Creatinine clearance (CrcL) ≥ 60 mL/min (Using the Cockcroft-Gault formula);
Liver function:
- Total bilirubin (TBIL) ≤ 1.5 × ULN;
- Aspartate amino transferase( AST) and Alanine amino transferase (ALT) 2.5 × ULN, or ≤ 5 × ULN in patients with hepatic metastasis or primary liver cancer;
- Alkaline phosphatase (ALP) ≤ 2.5 ×ULN, or ≤ 5 × ULN in patients with hepatic metastasis or primary liver cancer;
- Women of childbearing age should agree that contraceptive measures (such as intrauterine device or condoms) must be used within study period and within 6 months after the end of the study; the serum or urine pregnancy tests is negative within 7days prior to the study for non-lactating patients; men should agree to use contraceptive measures during the study period and within 6 months after the end of the study period;
- Patients must give informed consent to this study before the trial, and voluntarily sign the written informed consent.
Exclusion Criteria:
- The patient has received chemotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy and other anti-tumor treatments or participated in other clinical trials within 4 weeks before the first use of the study drug, or within 5 half-lives of the treatment drug, whichever is longer;
- The patient has received platinum-based therapy within 3 months prior to the study drug;
- The patient has undergone major organ surgery (excluding needle biopsy) or suffered significant trauma within 4 weeks before the first use of the study drug;
- The patient has received nephrotoxic or ototoxic drugs such as cephalosporin, aminoglycoside antibiotics, amphotericin B within 14 days before the first use of the study drug;
- Those who are allergic to any excipients of the study drug or cisplatin and other platinum-based drug or have a history of severe allergies;
- Any unresolved toxicities from prior anti-tumor therapy (including radiotherapy) greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1(except for alopecia or other adverse reactions judged no safety risk by the investigators);
- Patients with clinical symptoms of central nervous system metastases or meningeal metastases, or there is other evidence that the patient's central nervous system metastases or meningeal metastases have not been controlled, and the investigators judge that they are not suitable for enrollment;
- The patient has active infectious disease;
- The patient has a history of autoimmune disease, immunodeficiency, including positive HIV test, or has other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;
- Active hepatitis B (hepatitis B virus titer > 1000 copies/mL or 200 IU/mL), prophylactic antiviral therapy other than interferon is allowed; hepatitis C virus infection;
- Patients with a history of severe cardiovascular disease, or severe renal dysfunction, bone marrow insufficiency, chickenpox, herpes zoster, gout, hyperuricemia, or a history of other serious systemic diseases, as judged by the investigator who are not suitable to participate in clinical trials;
- Known alcohol or drug dependence;
- Patients with ototoxicity (except high-frequency elderly hearing loss) or other neurotoxicity ≥ grade 2 assessed by audiometer;
- Patients with known visual impairment who are deemed unsuitable for participation in this study by the investigator;
- Previous history of clear neurological or psychiatric disorders, including epilepsy or dementia;
- Pregnant or breastfeeding females;
- Patients with history of other malignancies within 3 years before the first use of the investigational drug, except for the following: cured basal cell or squamous cell skin cancer, superficial bladder cancer, prostate cancer in situ, cervical cancer in situ, breast cancer in situ, etc. locally curable cancer, or persistent disease-free survival within 3 years;
- The investigator believes that the patients are not suitable to participate in this clinical study for other reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cisplatin micelle injection (HA132)
Dose-escalation: Five dose levels have been selected for evaluation in the Phase Ⅰ of the study. Dose escalation decisions will be determined based on toxicities observed during the first cycle. Dose-expansion: Patients will be administered HA132 at one or two dose levels (e.g. MTD and the dose below MTD). Cohort-expansion: Patients will be administered HA132 at one or two dose levels (e.g. MTD and the dose below MTD). |
HA132 will be administered intravenously (IV), once per 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Dose-limiting Toxicities (DLTs) in Stage I
Time Frame: Day 1 to 21 of Cycle 1 (each cycle of 21 days).
|
Day 1 to 21 of Cycle 1 (each cycle of 21 days).
|
|
Incidence of adverse events in Stage I
Time Frame: From Baseline (Day 1) up to 28 days post last dose.
|
Patients will be assessed for incidence and severity of adverse events(AEs) according to NCI-CTCAE criteria.
|
From Baseline (Day 1) up to 28 days post last dose.
|
Maximum tolerated dose (MTD) in Stage I
Time Frame: Day 1 to 21 of Cycle 1 (each cycle of 21 days).
|
Day 1 to 21 of Cycle 1 (each cycle of 21 days).
|
|
Recommended phase 2 dose (RP2D) in Stage I
Time Frame: Day 1 to 21 of Cycle 1 (each cycle of 21 days).
|
The RP2D will be determined based on safety data including DLT, preliminary efficacy data,and PK data.
|
Day 1 to 21 of Cycle 1 (each cycle of 21 days).
|
Objective Response Rate (ORR) in stage Ⅱ
Time Frame: Up to approximately 2 years.
|
Proportion of patients whose best overall response is CR or PR in studies assessed according to RECIST v1.1.
|
Up to approximately 2 years.
|
Confirmed objective response rate (ORR) in stage Ⅱ
Time Frame: Up to approximately 2 years.
|
During the study period, the best overall response is the proportion of patients with confirmed CR or PR (ie, CR+PR) as assessed by Response Evaluation Criteria in Solid Tumors.(RECIST
v1.1).
|
Up to approximately 2 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK Indicator: Area under plasma concentration vs time curve(AUC)、Peak plasma concentration(Cmax)、Terminal Half Life(T1/2).
Time Frame: Day 1 of Cycle 1 up to Day 1 of Last Cycle.
|
Day 1 of Cycle 1 up to Day 1 of Last Cycle.
|
|
ORR in Stage I
Time Frame: Up to approximately 2 years.
|
Up to approximately 2 years.
|
|
Confirmed ORR in Stage I
Time Frame: Up to approximately 2 years.
|
Up to approximately 2 years.
|
|
Progression-free survival (PFS)
Time Frame: Up to approximately 2 years.
|
Progression-free survival is defined as the time from the patient's first dose of study treatment (HA132) to the first date of either disease progression or death, whichever occurs first.
|
Up to approximately 2 years.
|
Disease control rate (DCR)
Time Frame: Up to approximately 2 years.
|
Proportion of patients whose best overall response is CR, PR or SD in studies assessed according to RECIST v1.1.
|
Up to approximately 2 years.
|
Duration of response (DOR)
Time Frame: Up to approximately 2 years.
|
The DOR for a responder is defined as the time from the patient's initial objective response to the first date of either disease progression or death, whichever occurs first.
|
Up to approximately 2 years.
|
Incidence of Adverse Events and Serious Adverse Events (SAEs) in stage Ⅱ
Time Frame: Up to approximately 2 years.
|
Up to approximately 2 years.
|
|
Estimated glomerular filtration rate (eGFR) and creatinine clearance
Time Frame: Up to approximately 2 years.
|
Up to approximately 2 years.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HA132C-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Malignant Solid Tumors
-
AnewPharmaCompletedAdvanced Malignant Solid TumorsChina
-
Daiichi Sankyo Co., Ltd.CompletedAdvanced Solid Malignant TumorsJapan
-
Daiichi Sankyo Co., Ltd.Completed
-
Puma Biotechnology, Inc.Completed
-
Puma Biotechnology, Inc.CompletedAdvanced Malignant Solid TumorsJapan
-
Daiichi Sankyo Co., Ltd.Terminated
-
AnewPharmaCompleted
-
GeneQuantum Healthcare (Suzhou) Co., Ltd.Recruiting
-
Stemirna TherapeuticsPeking University Cancer Hospital & InstituteNot yet recruitingAdvanced Malignant Solid Tumors
-
HutchmedRecruitingAdvanced Malignant Solid TumorsChina
Clinical Trials on Cisplatin micelle injection (HA132)
-
Ain Shams UniversityMisr International UniversityRecruitingNon Small Cell Lung Cancer | Cardiotoxicity | NephropathyEgypt
-
University of Missouri-ColumbiaRecruitingOropharynx Cancer | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Cancer of the Head and Neck | Throat CarcinomaUnited States
-
Institut du Cancer de Montpellier - Val d'AurelleActive, not recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingAdvanced Esophageal Squamous Cell CarcinomaChina
-
Hua LiRecruitingUnresectable Intrahepatic CholangiocarcinomaChina
-
Third Military Medical UniversityRecruitingSmall Cell Lung Cancer | Lung Cancer | SCLC, Extensive StageChina
-
Sun Yat-sen UniversityRecruitingNasopharyngeal CarcinomaChina
-
Jules Bordet InstituteRecruiting
-
EpicentRx, Inc.Prothex Pharma, Inc.Completed